Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $150M
Total Funding: $210M
Total Funding: $440M
Total Funding: $200M
Total Funding: $63M
Total Funding: $120M
Total Funding: $130M
Total Funding: $110M
2023
2023
Biotech investment firm focused on early, mid, and late-stage private companies
2021 - 2023
2021 - 2023
Biotech venture capital firm focused on early, mid, and late-stage private and small-cap public companies
2016 - 2020
2016 - 2020
Biotech venture capital firm focused on early, mid, and late-stage private companies Notable deals include: VelosBio (acquired by Merck for $2.75b): Co-led Series A financing Imara (IMRA): Co-led Series B financing Harpoon Therapeutics (HARP): Co-led Series B financing Aura Biosceinces: Co-led Series C financing
2012 - 2016
2012 - 2016
Life sciences investment firm that focuses on venture growth investments in drug development and medical technology
2011 - 2012
2011 - 2012
Healthcare practice with an emphasis in early-stage biotechnology and pharmaceuticals
2010 - 2010
2010 - 2010
2009 - 2009
2009 - 2009
BioOncology Pipeline Market Planning for T-DM1
2006 - 2008
2006 - 2008
Life sciences strategy consulting firm focused on pharmaceutical, biotechnology, and private equity clients
2004 - 2006
2004 - 2006
Financial services strategy consulting firm focused on banks, insurers, and private equity clients
2004 - 2004
2004 - 2004